|Bid||10.11 x 800|
|Ask||10.13 x 3200|
|Day's Range||9.96 - 10.47|
|52 Week Range||2.43 - 51.03|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Despite recent troubles, Canopy Growth is optimistic its cannabis beverages can dwarf the growth of hard seltzers.
Shares of Canopy growth (CGC) are trading 30% lower since its latest quarterly results last week. However one analyst sees share as undervalued for the Canadian cannabis company which has shifted from medical to more recreational sales when that market was legalized in Canada almost two years ago. “Although we expect the medical market to shrink because of recreational legalization, we forecast more than 10% average annual growth for the entire Canadian market through 2030, driven by the conversion of black-market consumers into the legal market and new cannabis consumers,” analyst Kristoffer Inton wrote in a note to investors.
A pair of marijuana stocks, Tilray (NASDAQ: TLRY) and OrganiGram Holdings (NASDAQ: OGI), both dropped notably in price on Friday (by 5.2% and 7%, respectively). The culprit seems to be another weed title, Canopy Growth (NYSE: CGC), which earlier in the day published an awful quarterly earnings release. Canopy Growth is a leading company in the sector.
Inside the best performing stocks in the top cannabis ETF of May.
Canadian cannabis company Tilray's (NASDAQ: TLRY) CEO believes that at least 12 marijuana companies will go under this year. In March, Tilray announced that it would be raising $90.4 million through an offering, largely because the company still could. CEO Brendan Kennedy told BNN Bloomberg that he "wasn't sure anyone was going to be able to raise any money in this industry again" and that "when we had the opportunity to strengthen the balance sheet, we did."
Colorado Representative Ed Perlmutter joins Yahoo Finance’s Zack Guzman to discuss the future of cannabis in the U.S., along with his outlook on future stimulus legislation.
Ladies and gentlemen, thank you for standing by, and welcome to Tilray's First Quarter 2020 Earnings Conference Call. Good afternoon, and thank you for joining us on Tilray's first quarter 2020 earnings conference call and webcast. On with me today are Brendan Kennedy, Chief Executive Officer; and Michael Kruteck, Chief Financial Officer.
Tilray's (NASDAQ:TLRY) 55% year-to-date loss is, without question, really bad. But it could have been much worse. Actually, it was much worse. At one point in March, Tilray had plunged nearly 90%.
Fortune 500 companies looking to invest in the cannabis sector are approaching with less fear than 18 months ago, according to Tilray’s chief executive officer.
Tilray Inc (TLRY) delivered earnings and revenue surprises of -11.36% and 4.85%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What happened Tilray (NASDAQ: TIL) shareholders outperformed a strong market last month. The stock rose 17% compared to a 13% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.
With the global economy withering under the COVID-19 pandemic, the odds of a wave of bankruptcies wiping out underperforming cannabis firms are on the rise.
Investors are “anxious” about the markets, but “aggressive’’ about investment opportunities, Caleb Silver, editor-in-chief of Investopedia, told Yahoo Finance.